Study guide
22.1 Acute Leukaemias
MRCP UK
Track your progress as you read
Finished sections get a check mark.
1 MRCP(UK) Part 1: Exam Overview, Blueprint & Strategy
1.1 Part 1 Format, Delivery and Fees 1.2 The Official Blueprint and Mark Allocation 1.3 Scaled Scoring, Attempt Limits and Best-of-Five Technique
2 Clinical Sciences: Cellular, Genetic & Molecular Medicine
2.1 Organelles, Cytoskeleton & Membrane Transport 2.2 Cell Cycle Control, Apoptosis & Cell Signalling 2.3 Mendelian & Non-Mendelian Inheritance 2.4 Trinucleotide Repeat Disorders & Chromosomal Abnormalities 2.5 Purine, Pyrimidine Metabolism & the Porphyrias 2.6 Glycogen, Lipid Storage & Amino Acid Disorders
3 Clinical Sciences: Anatomy, Physiology & Immunology
3.1 Clinical & Cross-Sectional Anatomy 3.2 Systemic Clinical Physiology & Homeostasis 3.3 Clinical Immunology & Hypersensitivity Reactions
4 Clinical Sciences: Statistics, Epidemiology & Trial Design
4.1 Study Designs & Evidence Hierarchy 4.2 Diagnostic Testing, Screening & Predictive Values 4.3 Statistical Analysis & Risk Quantification
5 Clinical Pharmacology, Therapeutics & Toxicology
5.1 Pharmacokinetics & Pharmacodynamics 5.2 Cytochrome P450 Systems & High-Risk Drug Interactions 5.3 Adverse Drug Reactions & Therapeutic Drug Monitoring 5.4 Paracetamol & Salicylate Poisoning 5.5 Toxidromes, Antidotes, Carbon Monoxide & Toxic Alcohols
6 Cardiology: Coronary Artery Disease & Heart Failure
6.1 Acute Coronary Syndromes & Myocardial Infarction 6.2 Heart Failure & Cardiomyopathies 6.3 Cardiac Assessment & ECG Interpretation
7 Cardiology: Arrhythmias, Valvular & Pericardial Disease
7.1 Atrial Fibrillation, Narrow & Broad Complex Tachycardias 7.2 Bradyarrhythmias, Conduction Block & Antiarrhythmic Drugs 7.3 Valvular Heart Disease & Murmur Interpretation 7.4 Infective Endocarditis 7.5 Pericardial & Acute Aortic Diseases
8 Respiratory Medicine: Airway & Parenchymal Lung Disease
8.1 Asthma: Diagnosis, Chronic Management & Acute Attacks 8.2 COPD: GOLD Staging, Stable Management, Exacerbations & NIV 8.3 Interstitial Lung Disease & Sarcoidosis 8.4 Respiratory Infections & Bronchiectasis
9 Respiratory Medicine: Vascular, Pleural & Sleep Disorders
9.1 Venous Thromboembolism & Pulmonary Embolism 9.2 Pleural Effusion & Pneumothorax 9.3 Respiratory Failure & Sleep-Disordered Breathing
10 Gastroenterology: Luminal Gastrointestinal Disease
10.1 GORD, Barrett's Oesophagus & Oesophageal Motility Disorders 10.2 Peptic Ulcer Disease, Helicobacter pylori & Zollinger-Ellison Syndrome 10.3 Crohn's Disease, Ulcerative Colitis & Extraintestinal Manifestations 10.4 IBD Medical Therapy, Coeliac Disease & Malabsorption 10.5 Acute Upper Gastrointestinal Bleeding: Risk Scores, Ulcer & Variceal Haemorrhage 10.6 Lower Gastrointestinal Disorders & Colonic Neoplasia
11 Gastroenterology: Liver, Biliary & Pancreatic Disease
11.1 Viral Hepatitis A to E 11.2 Autoimmune Hepatitis & Metabolic Liver Disease 11.3 Cirrhosis & Complications of Portal Hypertension 11.4 Cholestatic Liver Disease: PBC and PSC 11.5 Gallstone Disease, Biliary Sepsis & Pancreatitis
12 Endocrinology & Diabetes: Diabetes & Thyroid
12.1 Diabetes: Diagnostic Thresholds, Classification & Pathophysiology 12.2 NICE-Directed Type 2 Therapy & Microvascular Complications 12.3 Acute Diabetic Emergencies (DKA & HHS) 12.4 Thyrotoxicosis, Thyroiditis & Management of Hyperthyroidism 12.5 Hypothyroidism, Subclinical Disease & Thyroid Nodules
13 Endocrinology & Diabetes: Adrenal, Pituitary & Calcium
13.1 Hypopituitarism, Pituitary Apoplexy & Hyperprolactinaemia 13.2 Acromegaly, Diabetes Insipidus & SIADH 13.3 Cushing's Syndrome: Aetiology, Screening & Localisation 13.4 Adrenal Insufficiency & Endocrine Hypertension 13.5 Calcium Regulation & Hypercalcaemia 13.6 Hypocalcaemia & Metabolic Bone Disease
14 Renal Medicine: AKI, Glomerular & Tubulointerstitial Disease
14.1 Acute Kidney Injury & Chronic Kidney Disease 14.2 Nephrotic and Nephritic Syndromes & Primary Glomerular Disease 14.3 Rapidly Progressive Glomerulonephritis 14.4 Tubulointerstitial & Inherited Renal Diseases
15 Renal Medicine: Fluid, Electrolytes & Acid-Base Balance
15.1 Sodium & Water Disorders 15.2 Potassium, Magnesium & Phosphate Disorders 15.3 Acid-Base Disorders & Blood Gas Analysis
16 Neurology: Cerebrovascular, Headache & Demyelinating Disease
16.1 Stroke Classification, Brainstem Syndromes & Hyperacute Reperfusion 16.2 Secondary Prevention, TIA, Carotid Surgery & Intracranial Haemorrhage 16.3 Headache Disorders & Cranial Neuralgias 16.4 Multiple Sclerosis & Central Demyelinating Diseases
17 Neurology: Epilepsy, Movement Disorders & Neuromuscular Disease
17.1 Epilepsy & Acute Seizures 17.2 Movement Disorders & Cognitive Impairment 17.3 Neuromuscular Junction & Peripheral Nerve Disorders
18 Rheumatology: Inflammatory Arthritis & Connective Tissue Disease
18.1 Rheumatoid Arthritis: Pathophysiology, Clinical Features & Diagnosis 18.2 DMARDs, Biologics & Their Toxicities 18.3 Seronegative Spondyloarthropathies 18.4 Systemic Lupus Erythematosus & Drug-Induced Lupus 18.5 Systemic Sclerosis & Scleroderma Renal Crisis 18.6 Sjogren's Syndrome & Inflammatory Myopathies
19 Rheumatology: Systemic Vasculitis & Crystal Arthropathy
19.1 Vasculitis Classification, Large and Medium Vessel Disease 19.2 ANCA-Associated and Immune Complex Small Vessel Vasculitis 19.3 Gout & Calcium Pyrophosphate Deposition Disease
20 Infectious Diseases & Tropical Medicine
20.1 Sepsis-3 Definitions & the Sepsis Six 20.2 Bacterial Meningitis, CSF Interpretation & Toxic Shock Syndrome 20.3 Tuberculosis: Pathogenesis & Clinical Manifestations 20.4 Tuberculosis: Diagnosis & Anti-Tuberculous Therapy 20.5 HIV Infection & Opportunistic Diseases 20.6 Malaria: Species, Life Cycle & Severe Disease 20.7 Enteric Fever, Arboviral Infection & Tissue Parasites
21 Haematology: Anaemias & Red Cell Disorders
21.1 MCV-Based Diagnostic Approach to Anaemia 21.2 Haemolytic and Autoimmune Haemolytic Anaemias 21.3 Membranopathies, Enzymopathies, PNH & Sickle Cell Disease
22 Haematology: Malignancy, Coagulation & Transfusion Medicine
22.1 Acute Leukaemias 22.2 Chronic Leukaemias & Myeloproliferative Neoplasms 22.3 Lymphomas & Plasma Cell Dyscrasias 22.4 Coagulation Cascade & Inherited Bleeding Disorders 22.5 Thrombocytopenia & Thrombotic Microangiopathies 22.6 Transfusion Products & Acute Transfusion Reactions
23 Psychiatry in General Medicine
23.1 Mood & Psychotic Disorders in Medical Patients 23.2 Psychiatric Emergencies & Substance Misuse 23.3 Mental Capacity & UK Mental Health Law
24 Geriatric Medicine
24.1 Comprehensive Geriatric Assessment, Frailty, Delirium & Falls 24.2 Polypharmacy, Deprescribing & Pressure Ulcers
25 Dermatology
25.1 Inflammatory Skin Disease, Immunobullous Disorders & Severe Drug Eruptions 25.2 Cutaneous Malignancy
26 Oncology & Palliative Medicine
26.1 Neutropenic Sepsis, Spinal Cord Compression & SVC Obstruction 26.2 Hypercalcaemia of Malignancy & Tumour Lysis Syndrome 26.3 Palliative Care & End-of-Life Symptom Control
27 Medical Ophthalmology
27.1 The Acute Red Eye & Sudden Painless Visual Loss 27.2 Retinopathy in Systemic Disease
22.1 Acute Leukaemias
Key Takeaways Explain This Topic AI
Auer rods indicate acute myeloid leukaemia; the t(15;17) PML-RARA translocation defines acute promyelocytic leukaemia.
Acute promyelocytic leukaemia presents with severe disseminated intravascular coagulation and requires immediate all-trans retinoic acid before genetic confirmation returns.
The Philadelphia chromosome t(9;22) in acute lymphoblastic leukaemia confers a poorer prognosis and is an indication for tyrosine kinase inhibitor therapy.
Last updated: September 2026
Haematological malignancies encompass a heterogeneous spectrum of clonal neoplastic proliferations arising from myeloid or lymphoid lineages. In the MRCP(UK) Part 1 examination, success requires rapid recall of signature chromosomal translocations, immunophenotypic cell-surface clusters of differentiation (CD markers), characteristic peripheral blood film and histological findings, and urgent management protocols for acute oncological presentations.
1. Acute Leukaemias: AML & ALL
Acute leukaemias represent rapid, uncontrolled clonal expansions of immature haematopoietic progenitor cells (blasts) that arrest normal haematopoietic differentiation, rapidly leading to bone marrow failure.
Acute Myeloid Leukaemia (AML)
Epidemiology: Predominantly a disease of older adults (median age at diagnosis ~68 years).
Diagnostic Threshold: World Health Organization (WHO) diagnostic criteria define AML by the presence of >=20% blasts in the bone marrow or peripheral blood (or the presence of AML-defining recurrent cytogenetic abnormalities—such as t(8;21), inv(16), or t(15;17)—regardless of blast percentage).
Morphology & Cytochemistry: Myeloblasts are large cells with delicate, lacy chromatin, prominent nucleoli, and moderate basophilic cytoplasm containing Auer rods (fused, crystallized primary azurophilic granules containing peroxidase; pathognomonic of myeloid lineage ). Blasts stain strongly positive for myeloperoxidase (MPO) and Sudan black B.
Immunophenotyping: Expression of myeloid surface antigens: CD13+, CD33+, CD34+, and CD117+ (c-kit) .
Acute Promyelocytic Leukaemia (APML / AML M3 Subtype)
Cytogenetics & Molecular Mechanism: Balanced reciprocal translocation t(15;17)(q24;q21) , fusing the promyelocytic leukaemia ( PML ) gene on chromosome 15 to the retinoic acid receptor-alpha ( RARA ) gene on chromosome 17. The resulting PML-RARA oncoprotein represses transcription, causing absolute maturation arrest at the promyelocyte stage.
Clinical Emergency: Promyelocytes contain dense, abnormal azurophilic granules rich in tissue factor and annexin II. Cell breakdown releases massive procoagulant and fibrinolytic proteases, precipitating fulminant Disseminated Intravascular Coagulation (DIC) with widespread microvascular thrombosis and life-threatening haemorrhage (catastrophic intracranial or pulmonary bleeding).
Morphology: Promyelocytes packed with abundant azurophilic granules and stacked clusters/bundles of Auer rods within the cytoplasm, termed "faggot cells" .
MANDATORY EXAM RULE: If APML is clinically or morphologically suspected, EMERGENCY ORAL ALL-TRANS RETINOIC ACID (ATRA / tretinoin) MUST BE INITIATED IMMEDIATELY , without waiting for cytogenetic or molecular confirmation! ATRA binds to the mutated RARA receptor, forcing malignant promyelocytes to overcome the maturation block and differentiate into mature neutrophils. It is combined with arsenic trioxide (ATO) , producing cure rates >90% without conventional cytotoxic chemotherapy.
Differentiation Syndrome: Complication of ATRA/ATO therapy occurring 7–14 days after initiation; presents with fever, dyspnoea, bilateral pulmonary infiltrates, pleural/pericardial effusions, and acute renal failure. Managed by prompt initiation of high-dose intravenous dexamethasone (10 mg twice daily) .
Acute Lymphoblastic Leukaemia (ALL)
Epidemiology: The most common childhood malignancy (peak incidence 2–5 years); secondary smaller incidence peak in adults >60 years.
Morphology & Cytochemistry: Lymphoblasts have a high nuclear-to-cytoplasmic ratio, condensed chromatin, and inconspicuous nucleoli; MPO negative , but characteristically positive for terminal deoxynucleotidyl transferase (TdT) , a specialized DNA polymerase expressed exclusively in immature pre-B and pre-T lymphoblasts.
Immunophenotypic Subtypes:
B-cell ALL (85%): CD10+ (Common ALL Antigen / CALLA), CD19+, CD22+, CD79a+.
T-cell ALL (15%): CD2+, CD3+ (cytoplasmic and surface), CD5+, CD7+. Frequently presents in adolescent males as an anterior mediastinal mass causing superior vena cava (SVC) obstruction, stridor, and large pleural effusions.
Cytogenetic Stratification:
t(12;21)(p13;q22) ETV6-RUNX1 : Most common in children (~25%); carries an exceptionally favourable prognosis .
t(9;22)(q34;q11) BCR-ABL1 (Philadelphia chromosome): Occurs in 25–30% of adult ALL; historically confers an extremely poor prognosis, but outcome is dramatically improved by incorporating BCR-ABL tyrosine kinase inhibitors (imatinib, dasatinib) into chemotherapy.
Central Nervous System (CNS) Prophylaxis: Lymphoblasts cross the blood-brain barrier and colonize the leptomeninges (meningeal leukaemia: headache, cranial nerve palsies). Intrathecal chemotherapy (methotrexate and cytarabine) is a mandatory component of all curative ALL regimens.
Presentation and Emergency Complications
Acute leukaemia presents through marrow failure : anaemia causing fatigue and breathlessness, thrombocytopenia causing purpura, epistaxis and gum bleeding, and neutropenia causing fever and infection. Superimposed on this are complications of the leukaemic burden itself.
- Emergency Recognition Immediate action
- Neutropenic sepsis Fever with neutrophils 0.5 x 10^9/L or below Broad-spectrum antibiotics within one hour
Tumour lysis syndrome Hyperkalaemia, hyperphosphataemia, hyperuricaemia, hypocalcaemia Hydration plus allopurinol or rasburicase
Leukostasis White cell count above about 100 x 10^9/L with hypoxia or confusion Urgent leukapheresis and cytoreduction
DIC in acute promyelocytic leukaemia Bleeding with low fibrinogen, high D-dimer, prolonged PT Immediate ATRA plus aggressive blood product support
Leukostasis is far more common in AML than ALL at any given white cell count, because myeloblasts are larger and less deformable. Avoid red cell transfusion before cytoreduction where leukostasis is suspected, since raising the haematocrit worsens hyperviscosity.
Distinguishing AML from ALL
- Feature AML ALL
- Peak age Adults, rising with age Children; second smaller adult peak
- Blast morphology Auer rods; granular cytoplasm Scanty agranular cytoplasm
- Cytochemistry Myeloperoxidase positive Terminal deoxynucleotidyl transferase (TdT) positive
- Immunophenotype CD13, CD33, CD117 CD19, CD10 (B lineage); CD3 (T lineage)
- CNS and testicular disease Uncommon Common; requires intrathecal prophylaxis
- Mediastinal mass Rare Typical of T-cell ALL
- Prognostic Genetics
Cytogenetics dominate prognosis and therefore treatment intensity. In AML , t(15;17) PML-RARA , t(8;21) and inv(16) are favourable, NPM1 mutation without FLT3-ITD is favourable, while FLT3-ITD , complex karyotype and monosomy 7 or 5q deletion are adverse and push toward allogeneic transplantation in first remission. In ALL , the Philadelphia chromosome t(9;22) is the key adverse marker in adults and is now treated with a tyrosine kinase inhibitor added to chemotherapy; hyperdiploidy is favourable.
Acute promyelocytic leukaemia is the one subtype where treatment precedes confirmation. Suspicion alone — a young patient with pancytopenia, bleeding out of proportion to the platelet count, and hypergranular promyelocytes — justifies starting all-trans retinoic acid immediately, because early haemorrhagic death is the main cause of mortality and ATRA is rapidly effective. Differentiation syndrome (fever, dyspnoea, pulmonary infiltrates, weight gain, hypotension) is the principal complication of ATRA and is treated with dexamethasone.